Literature DB >> 1764225

Pharmacological studies of meisoindigo: absorption and mechanism of action.

X J Ji1, X M Liu, K Li, R H Chen, L G Wang.   

Abstract

Meisoindigo, an indirubin derivative, is a new type of cancer chemotherapeutic agent. It exhibited higher activity against rodent tumors than indirubin itself. Experiments have shown the improved absorption of meisoindigo, compared to indirubin to be one of the major reasons for the enhancement of antitumor activity. Studies on the mechanism of meisoindigo action indicate that it strongly inhibits DNA biosynthesis in tumor cells. Strong inhibition of the drug on assembly of microtubule protein was also obtained. By means of FCM technique the effects of meisoindigo on mouse leukemia L1210 cell cycle were examined. Experimental results showed that under the action of meisoindigo the S phase cells accumulated and the traverse of the cells in G2 + M phase to G1 phase may also be blocked to some extent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1764225

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  4 in total

Review 1.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

2.  Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.

Authors:  Yirong Li; Martin Ligr; James P McCarron; Garrett Daniels; David Zhang; Xin Zhao; Fei Ye; Jinhua Wang; Xiaomei Liu; Iman Osman; Simon K Mencher; Hebert Lepor; Long G Wang; Anna Ferrari; Peng Lee
Journal:  Clin Cancer Res       Date:  2011-05-23       Impact factor: 12.531

Review 3.  The role of plant-derived drugs and herbal medicines in healthcare.

Authors:  P A De Smet
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 4.  Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases.

Authors:  Tina Blažević; Elke H Heiss; Atanas G Atanasov; Johannes M Breuss; Verena M Dirsch; Pavel Uhrin
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-17       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.